Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 208.09B |
| Revenue (ttm) | 61.98B |
| Net Income (ttm) | 16.53B |
| Shares Out | n/a |
| EPS (ttm) | 6.51 |
| PE Ratio | 12.59 |
| Forward PE | n/a |
| Dividend | 2.93 (3.59%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 1,393 |
| Average Volume | 3,541 |
| Open | 81.50 |
| Previous Close | 81.20 |
| Day's Range | 81.50 - 81.70 |
| 52-Week Range | 77.40 - 125.60 |
| Beta | 0.36 |
| RSI | 39.91 |
| Earnings Date | Apr 24, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Shareholders of Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co...
Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK , March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: T...
Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Merck & Co., Inc.(MRK)
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc. (MRK) Shareholders
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investor...
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky about pending Class Action - MRK
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.
Merck subcutaneous Keytruda gains FDA target date in September
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and Febr...
Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co ("Me...
Merck plans US to launch subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA (pembrolizumab) in Pivotal 3475A-D77 Trial
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administratio...
Merck's Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
RAHWAY, N.J.--(BUSINESS WIRE)-- #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, eva...
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are...
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...